NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement equity grants to two non-executive new hires under its 2024 Inducement Plan on March 2, 2026. The Compensation Committee approved options for 10,000 ordinary shares at an exercise price of $32.83 and 2,200 restricted stock units.

Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over three years in equal one-third annual installments. Awards are subject to plan and award agreement terms and Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – NAMS

+3.05%

1 alert

+3.05% News Effect

On the day this news was published, NAMS gained 3.05%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current price: $30.14 Daily move: -3.34% Trading volume: 1,335,302 shares +5 more

8 metrics

Current price $30.14 Pre-news close on 2026-03-06

Daily move -3.34% Change over prior 24 hours before article

Trading volume 1,335,302 shares Today vs 20-day avg 870,791 (1.53x)

Inducement options 10,000 shares Aggregate options to two non-executive new hires

Option exercise price $32.83 Equal to NAMS Nasdaq closing price on March 2, 2026

RSU grants 2,200 shares Aggregate restricted stock units to two non-executive new hires

Option vesting period 4 years 25% after one year, then 36 monthly installments

RSU vesting period 3 years One-third vests on each annual anniversary

Market Reality Check

Price: $35.07 Vol: Volume 1,335,302 is eleva...

high vol

$35.07 Last Close

Volume Volume 1,335,302 is elevated vs 20-day average 870,791 (1.53x) ahead of this routine inducement grant news. high

Technical Shares at $30.14 are trading slightly above the $29.27 200-day MA but remain 28.24% below the $42.00 52-week high and above the $14.06 52-week low.

Peers on Argus

NAMS fell 3.34% with higher volume, while key biotech peers showed mixed moves: ...

NAMS fell 3.34% with higher volume, while key biotech peers showed mixed moves: several modest declines (e.g., MLYS -6.31%, RARE/CRNX -0.56%, VKTX -0.76%) and APLS up 0.30%, suggesting stock-specific factors rather than a uniform sector move.

Historical Context

5 past events · Latest: Feb 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Investor conferences	Neutral	-2.8%	Planned March investor conference participation and webcast availability.
Feb 18	Earnings and update	Neutral	+1.5%	Full-year 2025 results with regulatory, clinical and cash position update.
Feb 06	Inducement grants	Neutral	+2.0%	Inducement options for four new hires under 2024 Inducement Plan.
Feb 04	Conference presentation	Neutral	-0.0%	Announcement of virtual fireside chat at Guggenheim biotech summit.
Jan 09	Strategic update	Positive	-4.0%	2025 achievements, 2026 priorities and cash runway around key readouts.

Pattern Detected

Recent company updates, including conferences and prior inducement grants, have produced mixed price reactions, with some positive operational headlines coinciding with share price declines.

Recent Company History

Over the past few months, NewAmsterdam has focused on advancing obicetrapib and strengthening its financial position. Updates included 2025 achievements and 2026 priorities on Jan 9, an upcoming Guggenheim summit on Feb 4, larger inducement option grants on Feb 6, full-year 2025 results and a corporate update on Feb 18, and March investor conferences announced on Feb 25. Today’s smaller inducement grants under the 2024 Inducement Plan continue the pattern of equity-based compensation disclosures alongside ongoing clinical and corporate activity.

Market Pulse Summary

This announcement details routine equity inducement awards: options over 10,000 shares at an exercis...

Analysis

This announcement details routine equity inducement awards: options over 10,000 shares at an exercise price of $32.83 vesting over four years, and 2,200 RSUs vesting over three years. It follows prior equity-related disclosures and broader strategic updates in early 2026. Investors may track how such grants, alongside insider Form 4 activity and upcoming clinical or regulatory milestones, interact with the stock’s position near its $29.27 200-day moving average and below the $42.00 52-week high.

Key Terms

nasdaq listing rule 5635(c)(4), inducement share options, exercise price, restricted stock units, +3 more

7 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved the grant of inducement share options... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement share options financial

"approved the grant of inducement share options covering an aggregate of 10,000"

Inducement share options are stock options granted to a new hire as a special incentive to join a company, issued outside the company’s standard employee share plans. For investors, they matter because they create potential future dilution of existing shares and represent a cash‑free form of compensation that signals how much the company values attracting particular talent—like offering a signing bonus paid in future ownership rather than cash.

exercise price financial

"The share options have an exercise price per share equal to $32.83"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

restricted stock units financial

"approved the grant of restricted stock units covering an aggregate of 2,200"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"The shares subject to the options will vest over four years, with 25% of the shares vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

option award agreement financial

"subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement"

A written contract that grants an individual the right to buy company shares at a set price under specific conditions, like how many options they get, when they can exercise them, and when they expire. Think of it like a ticket that becomes valid only after certain milestones; it matters to investors because these agreements affect how many shares may enter the market, management incentives, and a company’s future earnings per share and dilution.

inducement plan financial

"pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. Not financial advice.

NAARDEN, the Netherlands and MIAMI, March 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 10,000 of NewAmsterdam’s ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $32.83, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on March 2, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 2,200 of NewAmsterdam’s ordinary shares to two non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units were granted on March 2, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

What inducement grants did NewAmsterdam (NAMS) approve on March 2, 2026?

NewAmsterdam approved options for 10,000 shares and 2,200 restricted stock units. According to NewAmsterdam, the awards were granted as inducements under the 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and grant date for the NAMS share options?

The options were granted on March 2, 2026 with an exercise price of $32.83. According to NewAmsterdam, that price equals the Nasdaq closing market price on the grant date.

How do the NAMS option vesting terms work for the new hires?

The options vest over four years: 25% after one year, then monthly over 36 months. According to NewAmsterdam, vesting is subject to each employee's continued service on applicable vesting dates.

What are the vesting terms for the 2,200 RSUs granted by NewAmsterdam (NAMS)?

The RSUs vest over three years with one-third vesting each year on the first, second and third anniversaries. According to NewAmsterdam, vesting is conditioned on continued service and the award agreement terms.

Were the inducement grants to NAMS executives or non-executive new hires?

The awards were granted to two non-executive new hires as inducements to join the company. According to NewAmsterdam, the Compensation Committee approved the grants under the 2024 Inducement Plan and Nasdaq rules.